The influenza (flu) virus is constantly undergoing a process of evolution and adaptation through acquiring new mutations.
WuXi fallout reverberates; Pharma’s top R&D spenders; Lilly teams up with Amazon; Historic NASH approval; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit